For instance, the effect of bevacizumab, a first-approved monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), was shown by phase III clinical trials to improve the response rate and survival of patients with non-small cell lung cancer (NSCLC) and colon cancer [8,9]. This evidence concerns the gene VEGFA and malignant colon neoplasm.